TGFB1 and idiopathic pulmonary fibrosis: A small molecule TGF-β inhibitor, pirfenidone (Esbriet®), has been approved as an agent for idiopathic pulmonary fibrosis in several countries and is currently one of the leading anti-fibrotic drugs in the field [159].